KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
88 hedge funds and large institutions have $265M invested in KalVista Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
13% more capital invested
Capital invested by funds: $234M → $265M (+$30.6M)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
1% less funds holding
Funds holding: 89 → 88 (-1)
2.01% less ownership
Funds ownership: 100.69% → 98.68% (-2%)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$12.3M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$6.8M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.4M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.25M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$4.95M |
| 3 |
Morgan Stanley
New York
|
-$4.79M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.07M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.01M |
KALV Hedge Fund Activity: Q1 2023 in Review
88 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2023, worth a combined $265M — up 13% from $234M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KALV and 18 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 23 added.
The largest buyer was Boxer Capital, opening a new position worth an estimated $12.3M. The largest seller was Fidelity Investments, cutting an estimated $9.25M.
- 88 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2023, down from 89 in Q4 2022.
- Funds reported $265M of KalVista Pharmaceuticals stock for Q1 2023, up 13% quarter-over-quarter.
- 18 funds opened new KalVista Pharmaceuticals positions in Q1 2023 and 19 closed out, a net change of -1 holder.
- The largest KalVista Pharmaceuticals buyer in Q1 2023 was Boxer Capital, an estimated $12.3M added.
- The largest KalVista Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $9.25M sold.
Based on aggregated 13F filings for Q1 2023.